A study of drug prescription patterns, disease-therapy awareness and of quality of life among patients with migraine visiting a tertiary care hospital in Mumbai, India

Authors

  • Shruti Bhide Department of Pharmacology and Therapeutics, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
  • Pragya Verma Department of Neurology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
  • Sangeeta Ravat Department of Pharmacology and Therapeutics, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
  • Chetan Phirke Department of Pharmacology and Therapeutics, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
  • Shirish Rao Department of Pharmacology and Therapeutics, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20233198

Keywords:

Drug prescription patterns, Disease therapy awareness, Migrane

Abstract

Background: Migraine is one of the leading causes of disability globally. There is scarcity of data on disease -therapy awareness and its correlation with demographic factors. Hence its was of interest to assess those along with quality of life in these patients.

Methods: A Cross-sectional observational study was conducted in108 patients attending the Neurology and headache OPD at a tertiary care hospital between March 2017 and August 2018. Disease and therapy awareness among patients were evaluated using validated questionnaires and correlation was done with demographic factors. The severity of the disease and its impact on the patients' quality of life were assessed using the migraine disability assessment scale.

Results: The mean disease and therapy awareness scores were 9 and 7 respectively. Both had a positive correlation with education and socioeconomic factors. The quality of life was affected moderately in 48.1% of the patients followed by severely 32.4% of the patients. The average number of drugs prescribed per encounter was 3.05. NSAIDS were used more commonly as compared to Triptans for acute attacks.

Conclusions: The disease and therapy awareness were fair and positively correlated with education/ socioeconomic status. However, a significant disability was found among patients even with treatment. This highlights the need for educating these patients for effectively controlling the disability.

References

Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd ed. USA: McGraw-Hill; 2013:33;629-808.

Vos T, Abajobir AA, Abbafati C, Abbas KM, Abate KH, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-59.

Beigin VL, Abajobir AA, Abate KH, Abd-Allah F, Abdulle AM, Abera SF, et al. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Dis. 2021;21:32-8.

Kulkarni G, Rao G, Gururaj G, Subbakrishna DK, Steiner T, Stovner LJ. The prevalence and burden of migraine in india: results of a population- based study in Karnataka state. J Headache Pain. 2014;15(1):18.

Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3-20.

Silberstein SD. Evidence- based guideline update: pharmacologic treatment for episodic migraine prevention in adults: American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337-45.

Pringsheim T, Davenport W, Mackie G. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39: S1-59.

Evers S, Afra J, Frese A. EFNS guideline on the drug treatment of migraine revised report of an EFNS task force. Eur J Neurol. 2009;16:968-81.

Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache- related disability. Neurology. 2001;56:23-8.

Silberstein SD. In: Benzon HT, Rathmell JP, Wu CL, Turk DC, Argoff CE, Hurley RW, eds. Practical Management of Pain. 5th ed. USA: Mosby; 2014:408-23.

Singh S, Sarda K, Hegde R. A pan-India study to assess the quality of life, symptom profile and management trends in patients with migraine: A cross- sectional study. J Assoc Physicians India. 2017;65(10):63-9.

Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16:12-8.

Bhatia M. Migraine: clinical pattern and psychiatric comorbidity. J Psychiatr. 2019.

Breslau N, Rasmussen BK. The impact of migraine: Epidemiology, risk factors, and co-morbidities. Neurology. 2001;56:61-8.

Ramasamy B, Karri M, Venkat S. Clinical profile and triggers of migraine: an Indian perspective. Int J Res Med Sci. 2019;7(4):1050.

Ong JJY, De Felice M. Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics. 2018;15(2):274-90.

Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute

migraine attacks in adults. Cochrane Database Syst Rev. 2016.

Rawat M, Joshi P. Drug utilization and quality of life in patients of migraine at a tertiary. Migrane J. 2018; 20:35-9.

WHO Collaborating Centre for Drug Statistics Methodology. Available at: https://www.whocc.no/. Accessed on 20 February 2023.

Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence- based guideline update: Pharmacologic treatment for episodic migraine prevention in adults report of the quality standards subcommittee of the American academy of neurology and the american headache society. Neurology. 2012;76:1337-45.

Goodhew SC. Migraine Literacy and Treatment in a University Sample. SN Compr Clin Med. 2019;1(10): 749-57.

Gupta R, Malhotra A, Malhotra P. An observational study to assess the knowledge of migraine among patients with migraine at a tertiary care teaching hospital. Int J Basic Clin Pharmacol. 2019;8(3):502.

Queiroz LP, Barea LM, Blank N. An epidemiological study of headache in Florianopolis, Brazil. Cephalalgia. 2006;26(2):122-7.

Mokdad AH, Forouzanfar MH, Daoud F, Mokdad AA, El Bcheraoui C, Moradi- Lakeh M, et al. Global burden of diseases, injuries, and risk factors for young people’s health during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387(10036):2383-401.

Sharma K, Remanan R, Singh S. Quality of life and psychiatric comorbidity in Indian migraine patients: A headache clinic sample. Neurol India. 2013;61(4):355-9.

Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK. A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache. 2017;57(10):13-9.

Downloads

Published

2023-10-25

How to Cite

Bhide, S., Verma, P., Ravat, S., Phirke, C., & Rao, S. (2023). A study of drug prescription patterns, disease-therapy awareness and of quality of life among patients with migraine visiting a tertiary care hospital in Mumbai, India . International Journal of Basic & Clinical Pharmacology, 12(6), 855–860. https://doi.org/10.18203/2319-2003.ijbcp20233198

Issue

Section

Original Research Articles